JP2005527599A5 - - Google Patents

Download PDF

Info

Publication number
JP2005527599A5
JP2005527599A5 JP2004500866A JP2004500866A JP2005527599A5 JP 2005527599 A5 JP2005527599 A5 JP 2005527599A5 JP 2004500866 A JP2004500866 A JP 2004500866A JP 2004500866 A JP2004500866 A JP 2004500866A JP 2005527599 A5 JP2005527599 A5 JP 2005527599A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
zonisamide
alkali metal
metal salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004500866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527599A (ja
Filing date
Publication date
Priority claimed from US10/429,474 external-priority patent/US20040029941A1/en
Application filed filed Critical
Publication of JP2005527599A publication Critical patent/JP2005527599A/ja
Publication of JP2005527599A5 publication Critical patent/JP2005527599A5/ja
Withdrawn legal-status Critical Current

Links

JP2004500866A 2002-05-06 2003-05-05 肥満および摂食障害におけるゾニサミドの使用 Withdrawn JP2005527599A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37844602P 2002-05-06 2002-05-06
US10/429,474 US20040029941A1 (en) 2002-05-06 2003-05-02 Zonisamide use in obesity and eating disorders
PCT/US2003/014459 WO2003092682A1 (en) 2002-05-06 2003-05-05 Zonisamide use in obesity and eating disorders

Publications (2)

Publication Number Publication Date
JP2005527599A JP2005527599A (ja) 2005-09-15
JP2005527599A5 true JP2005527599A5 (cg-RX-API-DMAC7.html) 2006-09-14

Family

ID=29406837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004500866A Withdrawn JP2005527599A (ja) 2002-05-06 2003-05-05 肥満および摂食障害におけるゾニサミドの使用

Country Status (5)

Country Link
US (2) US20040029941A1 (cg-RX-API-DMAC7.html)
EP (1) EP1503755A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005527599A (cg-RX-API-DMAC7.html)
AU (1) AU2003228933A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003092682A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003231788B2 (en) * 2002-05-17 2008-09-11 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043705A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154035A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
MXPA06012685A (es) * 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
WO2005113069A2 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
PT2135603E (pt) * 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3452041B1 (en) 2016-03-07 2026-01-14 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Compositions and methods for administering ppar-gamma-agonists, surfactant peptides and phospholipids
IL313825B2 (en) 2017-06-14 2025-07-01 Vertex Pharma Devices and methods for administering medications
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33965A (en) * 1861-12-17 Improvement in rifle-sights
US25038A (en) * 1859-08-09 Egg-beater or churn
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5853975A (en) * 1994-08-23 1998-12-29 Millennium Pharmaceuticals, Inc. Methods for identifying compositions for the treatment of body weight disorders, including obesity
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0915697B1 (en) * 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US6262049B1 (en) * 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
NZ513643A (en) * 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US6459003B1 (en) * 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6437147B1 (en) * 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
AU2003231788B2 (en) * 2002-05-17 2008-09-11 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso

Similar Documents

Publication Publication Date Title
JP2005537268A5 (cg-RX-API-DMAC7.html)
JP2002522485A5 (cg-RX-API-DMAC7.html)
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
JP2021512121A5 (cg-RX-API-DMAC7.html)
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
JP2009506054A5 (cg-RX-API-DMAC7.html)
JP2005515966A5 (cg-RX-API-DMAC7.html)
JP2006515351A5 (cg-RX-API-DMAC7.html)
JP2023116697A5 (cg-RX-API-DMAC7.html)
JP2004519493A5 (cg-RX-API-DMAC7.html)
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
JP2024516297A5 (cg-RX-API-DMAC7.html)
JP2004537500A5 (cg-RX-API-DMAC7.html)
KR20060032598A (ko) 세로토닌 재흡수 억제제 및 아고멜라틴의 조합
JP2002540148A5 (cg-RX-API-DMAC7.html)
JP2008516909A5 (cg-RX-API-DMAC7.html)
JP2007505156A5 (cg-RX-API-DMAC7.html)
JP2005513105A5 (cg-RX-API-DMAC7.html)
Smith et al. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck: A phase II Southwest Oncology Group study
US12551471B2 (en) ABT-751 and ionizing radiation
RU2005132175A (ru) Комбинированное лечение опухолей, включающее неморубицин и лучевую терапию
JPH0455172B2 (cg-RX-API-DMAC7.html)
Botea Analgesics
JP2004533434A5 (cg-RX-API-DMAC7.html)